2022-Global Acts-Annual-Report

2022 ACTS Annual Report
Statistical Quality Assurance applied to

IQVIA’s Information Offerings
Global Data Science and Advanced Analytics

(v20230228)
© 2023. All rights reserved. IQVIA ® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
Table of Contents
(please use hyperlinks for navigation)
+ Welcome
+ About this report
+ MIDAS
• Accuracy: Global & Regional Results
• Timeliness
• Specialty Markets
+ IQVIA Market Prognosis
+ Appendix
• Accuracy: Country/Channel Results
• Methodology
1
Welcome
Thank you for downloading the most recent ACTS annual report, IQVIA's Statistical Quality Assurance program. We are proud to publish the 2022 edition on the
IQVIA Customer Portal, serving as a quality measurement on MIDAS data offerings. Single country-pages available for download as validation results are ready for
sharing.
The report is labeled ‘2022 ACTS Annual Report’, which consolidates validation analyses on data spanning years 2017 thru 2021. Despite the uncertainty of COVID
pandemic, regional conflicts and economic volatility, we are most grateful for constant support from our clients to allow us continuing with this important program. We
are confident that the report will once again provide you valuable insight into IQVIA MIDAS offerings.
This new edition is a summary of ~90 single channel validation results. IQVIA analyzed data from 5000+ pharma companies and affiliates who shared data for
validation on 88,000+ product forms. The analyses produced quality measurements which enable readers to compare country-level results with each other and enable
IQVIA offering development teams and statistical methodologists to identify actions to improve quality of MIDAS.
ACTS country reports are available on the IQVIA Customer Portal, with country results being uploaded as soon as data has been thoroughly analyzed and validated.
If you are a customer portal user, please visit ACTS Country Reports under the MIDAS country coverage section and subscribe to new content by enabling Manage
IQVIA Alerts Subscriptions under ‘My Settings’. In this annual report, you will find single country reports in the Appendix.
If you have questions about the methodology being used for deriving the quality metrics Bias and Precision, and for Timeliness, please refer to the Methodology
section featured in the Appendix. For questions about this quality assurance program, please contact MIDAS Offering Management (MIDAS@iqvia.com), for technical
assistance or inquiries about accessing services on the IQVIA Customer Portal, please email eService@iqvia.com.
Yours sincerely,
Yilian Yuan,
Ph.D., MBA
SVP, Global Data Science and Advanced Analytics
Back 2
About this report
ACTS is a unique statistical quality assurance program, measuring data accuracy and timeliness of
IQVIA’s Information Offerings hosted on MIDAS
What ACTS is ACTS Data Basis
• ACTS stands for Accuracy and Timeliness Statistics, a globally implemented, Accuracy Timeliness
standardized and evidence-based quality assurance program that has been Distribution
Countries* Companies Packs Deliverables
in operation for more than 30 years. It validates IQVIA's information offerings Channels
of sales data for each product pack registered in a market with the help of Region
pharmaceutical companies. North America 2 4 600+ 11K 180+
• The manufacturers participating in the survey supply the ex-factory quantity Latin America 12 15 350+ 16K 260+
sold in the validated calendar year for each registered product pack. These Europe 22 44 3,100+ 39K 1,100+
are compared with IQVIA’s audits. Accuracy and timeliness indicators are Africa, M. East, S. Asia 11 11 400+ 8K 300+
derived from the analysis and reported in ACTS. Asia Pacific 10 12 500+ 12K 280+
• It provides cross-national comparability of quality measurements. The Total 57 86 5,000+ 88K 2,000+
validation results are published individually for each country and on the Channel
IQVIA Customer Portal and IQVIA Homepage. Retail (Sell-in) 32 32 1,200+ 35K 1,000+
• Timeliness of MIDAS data offerings is measured against target values (days Hospital (Sell-in) 3 3 150+ 1K 300+
after period) in a standardized way and published. Combined (Sell-in) 19 19 1,100+ 22K 250+
• As a special feature, ACTS reports the validity of IQVIA Market Prognosis Retail (Sell-out) 15 15 1600+ 20K 100+
and its forecasting accuracy. Hospital(Sell-out) 3 3 400+ 1K 300+
• The ACTS report is the only quality assurance program in our industry to Retail OTC 14 14 450+ 5K -
document the audits’ quality and timeliness transparently across countries. Total 57 86 5,000+ 88K 2,000+
*number of distinct countries
Back 3
MIDAS
The trusted industry gold standard in global market measurement
90+ 150+ 10K 1.6M 4M+

Distribution Molecule
Countries Products Packs
Channels Combinations
40+ years of local and

global experience Products Packs
(per year) (per year)
120+ production heads
in 7 countries NEW 82,000 267,000
Ongoing updates as new/changed

products and packs appear: CHANGED 46,000 236,000
Back 4
Accuracy: Global &
Regional Results
Back
5
Content covered in this section
Global & Regional Global and regional accuracy results and 5-years trend
Data Type Results by data type (Retail, Hospital, PharmaTrend/Sell-out, OTC)
Countries Impacted List of countries with improved or deteriorated results
6
Regions and countries validated
Geographical Coverage
Regions Countries
covered not covered
• North America • Australia
- United States • Belgium
- Canada • Chile
• Latin America • Estonia
• Europe • Germany
• Africa, Middle East, • India
South Asia (AMESA) • Philippines
• Asia Pacific (APAC) • Portugal
• Romania
• South Africa
• Sri Lanka
7
Global and Regional Results
Coverage Results Summary
• Several IQVIA audit data could not be Global Precision Index (%) • Global precision index in 2021 is
validated due to lack of previously 100 94.3 94.6 94.2 94.1 93.9 93.9%. It dropped slightly by 0.2%
participating companies in the 80
comparing with previous year.
respective countries: e.g. Australia,
India, Romania, Portugal. 60 • The global precision decrease is mainly
40
driven by North America region. The
• Countries paused validation of the most 0.9% drop in North America region is
20
recent calendar year as information due to additional blocked product sales
offerings were undergoing upgrade of 0 identified across multiple companies in
2017 2018 2019 2020 2021
data sources or statistical 2021. In spite of the decrease, North
methodologies or both: e.g. Belgium, Precision 2021 % Change vs. PY %p
America region still has the highest
Germany. precision of 95.5% among all regions.
World 93.9 -0.2
• IQVIA could not secure enough • AMESA region improved by 2.4% with
participating companies, yet the precision 93.6%.
Asia Pacific 79.8 -0.7
validation was conducted but not
published as the validated market
Europe 93.9 +0.3 • Asia Pacific region is with relatively low
share fell below a minimum threshold: Latin America 89.0 +1.8 precision of 79.8%, slight drop
e.g. Chile, Estonia, South Africa, AMESA 93.6 +2.4 comparing with previous year.
Spain Hospital. North America 95.5 -0.9
8
Countries with improved and deteriorated precision
Retail Validation Results
Global Retail Precision Index (%) Improvement Deterioration

100 94.9 95.5 94.9 94.9 94.7 Precision Change Precision Change
Country 2021 vs. 2020 Country 2021 vs. 2020
% %p % %p
80
Paraguay 65.8 +23.9 Morocco 88.8 -8.3
Bolivia 73.2 +13.0 Greece 88.5 -4.9

60
Uruguay 89.4 +12.6 South Korea 82.5 -3.8
40
Bangladesh 82.6 +10.0 Dom. Rep. 89.9 -3.0
Algeria 77.2 +7.8

20
0
2017 2018 2019 2020 2021
9
Hospital Validation Results
Global Hospital Precision Index (%) Improvement Deterioration

100 Precision Change Precision Change
91.7 90.9 91.9 90.8 89.9 Country 2021 vs. 2020 Country 2021 vs. 2020
% %p % %p
80
Austria 93.2 +3.9 Italy 78.3 -3.9
Russia 86.4 +3.2 Croatia 98.7 -0.8

60
Bosnia 99.3 +2.8
40
Kazakhstan 94.3 +2.8
20
0
2017 2018 2019 2020 2021
10
Pharmacy Sell-out (PharmaTrend PTR) Validation Results
Global PTR Precision Index (%) Improvement Deterioration

100 94.6 95.2 Precision Change Precision Change
94.2 93.6
92.0 2021 vs. 2020 Country 2021 vs. 2020
Country
% %p % %p
80
Italy 95.5 +3.6 Croatia 93.9 -5.3
Slovakia 96.4 +2.9 Switzerland 94.6 -1.8

60
Czech Republic 96.6 +2.2
40
20
0
2017 2018 2019 2020 2021
11
Retail OTC Validation Results
Global Retail OTC Precision Index (%) Improvement Deterioration

100 Precision Change Precision Change
90.9 90.8 91.6 Country 2021 vs. 2020 Country 2021 vs. 2020
87.5 88.8
% %p % %p
80
South Korea 80.6 +16.4 Greece 71.7 -13.2
Argentina 89.8 +8.0 Mexico 76.8 -8.7

60
Bulgaria 93.5 +4.6 Austria 88.3 -2.1
40
Switzerland 93.5 -1.9
20
0
2017 2018 2019 2020 2021
12
Timeliness
Back
13
Statistics featured in this section pertain to number of days, after the

Timeliness
end of the reporting period until time of delivery on MIDAS.
“Elapsed days after period” and “Percent On-Target” are the

Metrics two key performance indicators that express Timeliness/speed of
delivery on MIDAS.
Number of deliverables used for measuring Timeliness: Also reported

DAP Data
on IQVIA Customer Portal “MIDAS Delivery Performance”.
Timeliness being measured against delivery targets of 30 days for Monthly MIDAS and 45 days for Quarterly MIDAS; DAP data bei ng used is also published on MIDAS Delivery Performance:
https://customerportal.imshealth.com/sites/imsportal/product-support/midas-products-psa/iqvia-midas/psa/database-update-schedules
14
DAP continued improving on both monthly and quarterly
deliverables
Elapsed Days after Reporting Period (Average) Region Channel
Percent On-Target 2022 Percent On-Target 2022
35.0
30.2
29.3 28.5 76
30.0 27.9 27.7 76 All
World
Days
89 89
25.0 27.1 85
26.2 21 Retail
25.0 North America 93
24.2 23.9 100
20.0 77
2018 2019 2020 2021 2022 Hospital
69 86
Latin America
Monthly Quarterly 100
52
Non Retail
100
87
Percent On-Target Europe
95 27
Total Sales
100 87 89 89 100
85 86
72 73 76 Africa, Middle 92
80 70 100
63 East, South Asia 90 Combined
60 67
40 53 59
Asia Pacific Other
20 63 86
0
2018 2019 2020 2021 2022 Monthly Quarterly Monthly Quarterly
Monthly Quarterly
Timeliness being measured against delivery targets of 30 days for Monthly MIDAS and 45 days for Quarterly MIDAS DAP data bein g used is also published on MIDAS Delivery Performance:
15
Number of deliverables used for measuring Timeliness
2018 2019 2020 2021 2022
Month Quarter Month Quarter Month Quarter Month Quarter Month Quarter
Channel
Combined 60 32 60 32 60 32 60 32 60 32
Hospital 456 180 456 180 456 180 456 180 456 179
Non-Retail 36 12 36 12 36 12 36 12 36 12
Other 106 48 108 48 108 48 108 48 108 48
Retail 766 288 766 288 768 288 768 288 768 288
Total Sales 132 48 132 48 132 48 132 48 132 48
Total 1,556 608 1,558 608 1,560 608 1,560 608 1,560 607
Region
North America 132 48 132 48 132 48 132 48 132 48
Latin America 192 68 190 68 192 68 192 68 192 68
Europe 850 288 852 288 852 288 852 288 852 287
Africa, M. East,
216 92 216 92 216 92 216 92 216 92
S. Asia
Asia Pacific 166 112 168 112 168 112 168 112 168 112
Total 1,556 608 1,558 608 1,560 608 1,560 608 1,560 607
Timeliness being measured against delivery targets of 30 days for Monthly MIDAS and 45 days for Quarterly MIDAS DAP data bein g used is also published on MIDAS Delivery Performance:
16
Specialty Markets
Back
17
• MIDAS Specialty Definition

Definitions
• ATC 4th level definition of Specialty products
Global Growth • Specialty vs. Non-Specialty: Market size and market share
• Bias and Precision by Specialty markets (Anti-TNF, Hep-B & HIV,

Accuracy Results Oncology and Others)
• Data basis used: Countries and Specialty products surveyed
18
MIDAS Specialty Definition
Starting point – US specialty definition
• The starting point for the MIDAS specialty Researched Attributes (US)
definition is the IQVIA USA detailed definition
of a specialty product, which includes Approved indication is
Special handling required
(and/or) chronic,
concepts such as price, involvement of a complex, rare, genetic
(refrigeration, frozen,
specialist, form of administration, etc. other biohazard)
- REQUIRED -
• First, the approved indication must be
considered to be specialty (chronic and/or Reimbursement
complex and/or rare and/or genetic) for a High annual cost
assistance required
pack to be classified as specialty.
• The pack must then also meet 4 out of 7
other criteria to be classified as specialty. Drug treatment specialist
Distribution is limited
initiated and maintained
• These US products have formed the starting
point to identify similar products in other
countries to assess if they are specialty
using the MIDAS definition. In-depth monitoring or
Practitioner administered extensive patient
counselling required
19
ATC 4th level definition of Specialty
Anti-TNF Hepatitis B Crohn’s

Oncology Others***
& more* & HIV Disease**
L04B0 J05C1 L01A0 L01G1 L01H4 L01X5 L02B9 A07E0 A16A0 G03G0 J06H9
L04C0 J05C2 L01B0 L01G2 L01H5 L01X8 L03A1 A07E1 B02C1 H01C1 J06J0
L04X0 J05C3 L01C1 L01G3 L01H6 L01X9 L03A9 A07E2 B02C2 H01C2 L03B1
M01C0 J05C4 L01C2 L01G4 L01H9 L02A1 M05B4 A07E9 B02C3 H01C3 L03B2
J05C5 L01C3 L01G5 L01J0 L02A2 V03C0 B02C9 H02A1 L03B3
J05C9 L01C4 L01G9 L01L1 L02A3 V03D0 B02D1 H04C0 L03B9
J05D1 L01C9 L01H0 L01X1 L02A9 B02D2 H04E0 M05B3
J05D2 L01D0 L01H1 L01X2 L02B1 B02D3 J06C0 M05B9
J05D3 L01F0 L01H2 L01X3 L02B2 B03C0 J06E0
J05D9 L01G0 L01H3 L01X4 L02B3 G02X9 J06H4

*Anti-TNF, specific anti-rheumatic agents and immunosuppressants; ** not represented in this report; *** Acromegaly, Erythropoietins (Anemia), Gaucher's (Metabolic Disease), Growth hormones, Hemophilia,
Immunoglobulins, Infertility, INJ CORTICOSTEROIDS PLN, Interferons (Hepatitis C, MS),; Osteoporosis, Other Anticoagulants, Other Gynaecologicals, Parathyroid hormones
20
Specialty medicines will represent about 43% of global spending
in 2027 and 56% of total spending in developed markets
Specialty medicines share of spending
Forecast
56%
49%
39% 47%
40% 43%
36%
43%
28%
32%
27%
24%
16%
16%
12%
10%
2012 2017 2022 2027
10 developed Other developed Pharmerging Global

Source: IQVIA Institute, Nov 2022.
21
Specialty market “Anti-TNF &more” show largest improvement*
Accuracy Results Survey Basis

0.00 Hep B
Anti-TNF Oncology Others Crohn's All Specialty Groups
& HIV
-1.8 -1.6 Countries Austria France Austria Czech R. Canada Argentina Lithuania
-2.3 -2.1
Bias (%)
-2.6 surveyed Canada Switzerland Canada France Austria Mexico

-3.1 -2.8
-3.2 -3.5 Czech R. USA Croatia Hungary Bangladesh Morocco
-5.00 France Czech R. Italy Bulgaria Pakistan
-4.6
-5.0 Hungary France Pakistan Canada Peru
-5.8 Switzerland Hungary Russia Central Poland
Turkey Italy Serbia America Russia
USA Mexico Switzerland Colombia Saudi
Pakistan Turkey Croatia Arabia
-10.00 Poland USA Czech R. Serbia
Russia Dom. Rep. Slovakia
Serbia Ecuador Slovenia
Slovakia France South
Slovenia Greece Korea
99.6 100.0 99.6 93.9 88.7 100.0100.0 87.8 91.5 South Hungary Switzerland
100.0 80.6 78.0 Korea Italy Turkey
Precision (%)
74.2
Switzerland Kazakhstan UAE
Turkey Latvia Uruguay
50.0
UAE USA
USA
0.0
Anti-TNF Hepatitis B Oncology Others Crohn's All Specialty Specialty
& more & HIV disease Groups products 470 116 1,486 717 20 4,148
2020 2021 surveyed
*Due to low number of countries and products surveyed, the Accuracy results presented on this page require careful interpretation. A larger Specialty data base is planned for in the future.
22
IQVIA Market Prognosis
Back
23
IQVIA Market
What it is and what it is used for
Prognosis
Validity of Results by IQVIA’s regional BU and leading 10 pharmaceutical

Annual Forecast markets
Commentary Commentary on selected markets
24
IQVIA Market Prognosis
A strategic market forecasting publication that provides unparalleled country-level information on
the pharmaceutical and healthcare industries
Capabilities Use Cases
• Based on a rigorous evaluation of key events affecting the Customers can use IQVIA Market Prognosis to:
marketplace, IQVIA Market Prognosis provides a robust • Validate their forecasts to establish annual targets
five-year forecast at country, regional, and global levels.
• Set and manage expectations from corporate
• Customers can gain insights into the economic and headquarters to local subsidiaries
political issues affecting the local pharmaceutical and
healthcare industries such as cost containment, • Evaluate key economic and healthcare related issues in
prescribing and reimbursement, pricing trends, and the each country
regulatory environment. • Identify macro events shaping the pharmaceutical
• Forecasts are supported with detailed evaluation of the country markets
key issues affecting the marketplace. • Understand key drivers in the hospital and retail markets
• In-depth reports are available for 49 countries across over the next five years for each country market
7 regions. • Apply unrivalled world perspective on established and
• Market Prognosis Global extends coverage, providing top- emerging markets to determine future investments
line country forecasts across 220 countries in 11 regions.
25
Market Prognosis Validations: Key Findings
Despite the unforeseen impact of the COVID-19 pandemic, both 1-Year and 5-Year validations
showed very strong results
Average 5-year error across 45 Market Prognosis countries was

Global -4.9%, a slightly deterioration on previous average error of -3.0%.
The average error for year 5 of forecast was -8.4%.
Three of the five Market Prognosis regions showed deteriorated

5-year errors compared to previous validation. Latin America showed
Regional an improved 5-year error, North America’s 5-year error turned from
over-estimation to under-estimation, see slide 5-8 for explanation.
For the leading 10 countries, four of them showed 5-year average

Leading 10
errors greater than +/-5%, and five countries showed a 1-year error
Countries greater than +/-3%.
26
Market Prognosis
Validity of Annual Forecasts
Forecasting Bias (%) based on 45 Countries Leading 10 Markets Leading 10 Markets
10 5 years (2017-21) 1 year (2021)
5 US
USA +1.5 -2.3
0
-0.7 China +1.3 CN -0.1
-5 -3.6
-6.3 -5.6
-10 -8.4 Japan +0.1 JP -2.7
-15
Germany -6.7 GE +0.0
2017 2018 2019 2020 2021
France +0.3 FR -3.7

Average Bias (%)
Region Italy +0.5 IT -3.8
2016-2020 2017-2021
AMESA -3.1 -4.8 United Kingdom -2.7 UK -6.8
Asia Pacific -1.5 -3.1
Spain -7.6 SP -5.2
Europe -4.9 -7.0
Latin America -2.4 -1.9 Canada -6.3 CD -1.7
North America 4.6 -2.4 Brazil -5.4 BR -5.7

All Regions -3.0 -4.9
27
Market Prognosis on selected Markets
Commentary
United States China Japan

• The slight overestimation of 2017-2021 total market • The minor overestimation of total market growth in China • The forecast for Japan over the 2017-2021 period was in
growth in the US is the result of weaker than anticipated over the 2017-2021 period is the result of lower-than- line with expectation, while growth in 2021 was
annual list price increases in the early part of the forecast expected growth in 2017-2018, due to cost-containment underestimated in the 1-year forecast as the market
period, particularly for older brands and generics from measures, as well as in 2020, as a result of the COVID recovered surprisingly faster than anticipated from the
late 2016. Market growth was also marginally below 2019 crisis. Data enhancements introduced to the slowdown caused by the COVID-19 pandemic.
forecast due to a greater degree of price erosion from dominant hospital sector panel in January 2021, with
loss of exclusivity of some major brands than forecast. backdata adjustments to 2019, have also raised overall • Both retail and hospital sector saw stronger than
hospital sector growth over the period. expected rebound in 2021 as COVID-19 related
• Moderating price-driven growth for branded products restrictions were lifted. While the retail sector saw a
was accompanied by increasing deflationary pressure • The 1-year forecast for China for 2021 was on track. rebound in volume growth from the second half of 2021,
due to new generic entrants. Furthermore, heightened hospital sector sales showed recovery primarily driven
risk of broader legislative action during the mid-to-latter by high-priced oncology drugs.
years of the 2017-2021 period curtailed drug price
inflation and discouraged price increases for established
generics and older brands. In addition, the contribution to
growth from certain specialty products, including
hepatitis C drugs, moderated by 2016, which limited their
impact on growth over the 2017-2021 period.
• The underestimation of the 1-year forecast for 2021 was

due to a stronger-than-expected rebound following the
deceleration in growth witnessed in 2020 due to the
COVID-19 pandemic. Primary care visits and volume
trends gradually improved as patient visits increased
despite further outbreaks.
28
Commentary
Germany France Italy

• The 5-year outlook for the German pharmaceutical • The 5-year forecast for France over the 2017-2021 • Italy’s market growth over the 2017-2021 period was
market over the 2017-2021 period was underestimated period was on track, while the underestimation of growth in line with forecast, while the 1-year forecast
as a result of stronger-than expected cost-control for 2021 in the 1-year forecast was due to the market underestimated growth for 2021 due to the stronger
measures curbing overall rates of growth. rebound from the COVID-19 pandemic. than expected rebound during the second year of the
COVID-19 pandemic.
• Mandatory and voluntary discounts, reference pricing, • Both market sectors saw a stronger-than-expected
prescribing controls and the price moratorium effectively rebound in 2021. In the retail sector, this was driven • This occurred primarily due to a sharp increase in
offset the anticipated growth of the market due to new by growth in the average price per standard unit, lifted hospital sector price growth (on the back of a significant
product launches. Also, in the early part of the 2017- by the rapidly growing number of hospital prescriptions price contraction recorded in 2020); this was driven by
2021 period, product withdrawals due to dissatisfaction dispensed in the retail sector, while in the hospital sector demand for high-cost medicines following the resumption
with early benefit assessments as well as price both volume and price grew strongly as normal hospital of backlog treatment which had been postponed during
negotiations kept growth rates in check. operations resumed, amidst continuing waves of the the initial phase of the pandemic.
pandemic.
• Other restrictive measures such as eligibility of orphan
drugs for early benefit assessment and introduction of
measures to promote biosimilar use also curtailed
market growth.
• Furthermore, the COVID-19 pandemic related

disruptions in 2020 decelerated hospital sector growth.
29
Commentary
United Kingdom Spain Canada

• The underestimated forecast for the UK over the 2017- • The underestimation of total market growth in Spain from • The underestimation of the 5-year total pharmaceutical
2021 period was largely driven by the launch and uptake 2017-2021 is mainly the result of higher-than-expected market growth in Canada is primarily due to increased
of new innovative medicines. Sales in the dominant growth in the hospital sector over the period. Strong utilization of high-cost specialty drugs, which led to
hospital sector experienced strong double-digit growth hospital sales have been driven by a higher-than- strong double-digit price growth, especially in 2019, in
over the 2017-2021 period (excluding a COVID-induced expected price growth since 2017, a trend which the hospital sector. In the retail sector too, strong price
slowdown in 2020) fuelled by use of high-priced drugs, intensified during the COVID-19 pandemic in 2020, while growth was observed, driven by anti-cancer drugs
notably antineoplastic agents and orphan drugs. volumes contracted sharply due to the postponement of including anti-TNFs (Inflectra, Cimzia and Humira) and
non-urgent treatments. protein kinase inhibitors (Ibrance and Imbruvica), among
• In the retail sector, robust growth in 2019 was driven by others, in addition to five additional new oncology drug
significant price per standard unit increases registered • The political instability in Spain over the past four years launches that year, that propelled growth at a pace
for several unbranded drugs. In 2020, the use of high- has delayed the approval of the draft Royal Decree on above forecast.
priced medicines for blood/blood-forming organs, anti- Regulating the Financing and Pricing of Drugs and
diabetic agents, and significant price hikes of certain Medical Devices, which was expected to curb overall • Market growth in 2021 was marginally above
products, notably the antidepressant sertraline, rates of market growth. The ineffectiveness of measures expectations, partly due to stronger-than-expected
contributed to strong average price growth. aimed at limiting annual public pharmaceutical growth post the COVID-19 pandemic. Increased retail
expenditure growth in line with GDP growth has sector demand for acute therapies amidst the surge in
• The 1-year forecast underestimation of total market therefore contributed to the underestimation of the seasonal infections and improved access to hospital
growth in 2021 was largely due to a stronger than forecast in 2017-2021. services following the easing of COVID-19 restrictions
anticipated rebound in the hospital sector following the drove consumption of medicines. A shift in the average
COVID-induced slowdown in 2020. The recovery was • A quicker than expected recovery of hospital volumes in product mix in favour of more expensive therapies also
largely volume-driven, as hospital procedures picked up, 2021 also led to an underestimation of the 1-year contributed to higher-than-expected growth in 2021.
notably in the second half of the year. forecast. A major redesign of the hospital panel led to
significant back data changes to the MIDAS data, which
ultimately led to the market size being underestimated in
2020-2021.
30
Commentary
Brazil
• The 2017-2021 forecast underestimation is attributed to
various factors. A centrist government at the end of
2016, followed by a right-wing conservative government
in 2019, called for greater efficiencies, cost containment
and a reduction in healthcare spending, leading to a
conservative 5-year forecast. Additionally, after several
years of economic contraction, Brazil’s economy grew in
2017-2019, driving private healthcare and out-of-pocket
spending during this period.
• The resilient Brazilian pharmaceutical market

unexpectedly reached double-digit growth amidst the
COVID-19 pandemic in 2020, driven primarily by the
retail sector, as pharmacies became key providers of
care. Brazil’s lax approach to lockdowns also contributed
to strong retail sales. Following an initial decline in
hospital activity in 2020, the rescheduling of cancelled
non-emergency treatments boosted pharmaceutical
sales in 2021 resulting in extraordinary total market
growth. The underestimation of growth for 2021 was also
due in part to deteriorated patient profiles intensifying
demand and spending on drugs post the pandemic.
Additionally, the Pharmaceutical Market Regulatory
Agency (CMED) permitted higher price adjustments in
2021 to compensate for price adjustment suspensions in
2020 and higher than expected inflation.
31
Appendix
Back
32
Accuracy:
Country/Channel
Results
Back
33
Validated Countries/Regions by Channel
(please use hyperlinks for navigation)
Retail (Sell-in) Retail (Sell-in) Hospital (Sell-in) Combined (Sell-in) Retail OTC (Sell-in) Other (Sell-out)
+ Algeria + Lithuania + Canada + Bosnia and + Argentina Retail
+ Argentina + Mexico + China Herzegovina + Brazil + France
+ Austria + Morocco + South Korea + Croatia + Bulgaria + Greece
+ Bangladesh + Pakistan + Czech Republic + Canada + United Kingdom
+ Bolivia + Paraguay + Hong Kong + Mexico PharmaTrend
+ Brazil + Peru + Hungary + South Korea + Austria
+ Bulgaria + Saudi Arabia + Indonesia + Croatia
+ Canada + South Korea + Japan Retail OTC (Sell-out) + Czech Republic
+ Central America + Spain + Kazakhstan + Austria + Finland
+ Colombia + Thailand + Malaysia + Greece + Hungary
+ Dominican Republic + Tunisia + Poland + Hungary + Ireland
+ Ecuador + Turkey + Russia + Italy + Italy
+ Egypt + United A. Emirates + Serbia + Poland + Poland
+ Italy + Venezuela + Singapore + Slovakia + Serbia
+ Jordan + Slovakia + Spain + Slovakia
+ Kuwait + Slovenia + Switzerland + Spain
+ Latvia + Switzerland + Switzerland
+ Lebanon + Uruguay Hospital
+ USA + Austria
+ Vietnam + Italy
+ United Kingdom
34
United States of America + Canada
Countries
United States of America
Canada
Back 35
USA Retail + Non-Retail Validation Study
2021 Validation Study
Validation Results Distribution Channels Validated
Precision 95.0% Bias -7.3%
100 95.6 96.5 95.6 96.0 95.0

20
80
0
60
Precision
-6.4 -7.6 -7.5 -7.3

40 -11.6
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
Outcomes • Overall precision index declined by 1 percentage point in # Participating # Forms % Market
2021 Companies Validated Validated
• Overall underestimation improved by 0.2 percentage points
in 2021 74 1,263 80%
• Lower precision is expected for companies with blocked (-3 vPY) (-58 vPY) (-1% vPY)
product sales
Back 36
Canada Retail Validation Study

100.0 99.9 100.0 100.0 99.9
100 20
80
0
60 -0.9
-1.0 -1.3 -1.5 -2.1
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
Outcomes # Participating # Forms % Market

• Overall precision index declined slightly by 0.1 percentage Companies Validated Validated
points in 2021
• Overall underestimation increased by 0.6 percentage points
in 2021 270 5,993 95%
• No action required from the statistical point of view (+11 vPY) (-103 vPY) (no change vPY)
Back 37
Canada OTC Validation Study

100.0 100.0 100.0 100.0 99.7
100 20
80
1.4 2.0 1.6 1.2
0
60 -0.2
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

points in 2021
• Overall bias turned from 1.2% overestimation to 0.2%
underestimation in 2021 168 2,695 100%
Back 38
Canada Hospital Validation Study
Precision 100% Bias 0%

100.0 100.0 100.0 100.0 100.0
100 20
80
0.0 0.3 0.0
0
60 -0.1 -0.2
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

• Overall precision index remained 100% unchanged in 2021 Companies Validated Validated
• Overall bias index improved by 0.3 percentage points in
2021 123 1,165 95%
Back 39
Latin America
Countries
Argentina Colombia
Bolivia Dominican Republic
Brazil Ecuador
Central America Mexico
• Guatemala Paraguay
• El Salvador Peru
• Honduras Uruguay
• Nicaragua Venezuela
• Costa Rica
• Panama
Back 40
Argentina Retail Validation Study
Precision 97.2% Bias 0.5%

96.4 97.6 97.9 95.5 97.2
100 20
80
0.2 0.5
0
60 -0.2 -1.3 -2.1
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

• Overall precision index improved by 1.7 percentage points Companies Validated Validated
in 2021
• Overall overestimation increased slightly by 0.3 percentage
points in 2021 37 2,070 51%
• No action required from the statistical point of view (no change vPY) (+131 vPY) (+4% vPY)
Back 41
Argentina OTC Validation Study
100 89.7 91.3 89.8 20

85.6 81.8
80
0
60
-4.6 -3.1
-6.3 -5.9
40 -8.9
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 23 243 36%
• No action required from the statistical point of view (+1 vPY) (-6 vPY) (-5% vPY)
Back 42
Bolivia Retail Validation Study
100 20
80 73.2
60.2 0
60 53.6 56.3 53.8
-7.2
40
-20
20 -20.4
-23.0 -24.2
-25.5
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
Outcomes • Overall precision index improved by 13.0 percentage points # Participating # Forms % Market
in 2021 Companies Validated Validated
• Overall underestimation improved by 17.0 percentage
points in 2021 3 388 16%
• Fulfill sample design according to the new PM territorial (-43 vPY) (-1,035 vPY) (-36% vPY)
upgrade. Increase validation participation
Back 43
Brazil Retail Validation Study
100 94.3 93.8

87.8 89.3 20
80
0.7
0
60
-3.5 -1.5 -3.8
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
• Overall bias turned from 3.8% underestimation to 0.7%
overestimation in 2021 29 2,608 38%
• No action required from the statistical point of view (+2 vPY) (+1,342 vPY) (+23% vPY)
Back 44
Brazil OTC Validation Study
100 96.1
91.6 20
87.1
78.2
80 3.6
0
60
-1.1
-4.1
40 -11.1
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
overestimation in 2021 23 574 26%
• No action required from the statistical point of view (+5 vPY) (+322 vPY) (+16% vPY)
Back 45
Central America Retail Validation Study
100 94.6 91.2 90.9

88.3 20
84.5
80
0
60
-2.3 -4.2
-4.8
40 -8.9 -8.7
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
Outcomes • Overall precision index declined by 0.3 percentage points in # Participating # Forms % Market
2021 Companies Validated Validated
in 2021 23 1,080 17%
• Adjust projection level and implement new projection (+7 vPY) (+103 vPY) (+3% vPY)
structure
Back 46
Colombia Retail Validation Study
100 20
84.3 87.0 12.1
80.8 80.6 81.8
80
0
60
-1.4
-5.0
40 -11.3
-20 -13.2
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
• Overall underestimation increased by 1.9 percentage
points in 2021 30 1,437 34%
Back 47
Dominican Republic Retail Validation Study
100 92.9 89.9 20

85.5
80.7 80.9
80
0
60 -0.2
-2.2
-4.8 -6.4
40 -8.5
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

• Overall precision index declined by 3 percentage points in Companies Validated Validated
2021
• Overall underestimation improved by 2 percentage points in
2021 16 1,042 20%
Back 48
Ecuador Retail Validation Study
100 94.1 91.3 92.9 91.7 89.1 20
80
0
60
-1.3 -2.7 -2.5 -3.5
-4.0
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

• Overall precision index declined by 2.6 percentage points in Companies Validated Validated
2021
in 2021 66 1,852 53%
• No action required from the statistical point of view (+22 vPY) (+83 vPY) (-2% vPY)
Back 49
Mexico Retail Validation Study
100 20
85.2 87.0 83.9 85.2
80.7
80
0
60
-4.7 -5.4
40 -9.3 -9.5
-20 -13.5
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 32 964 16%
• Review projection structure (-2 vPY) (-23 vPY) (+2% vPY)
Back 50
Mexico OTC Validation Study
100 92.5 95.9

20
85.5
79.1 76.8
80
1.4
0
60
-2.5 -1.0
40 -9.8
-20 -17.1
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

2021
underestimation in 2021 12 143 10%
• Review projection structure (no change vPY) (+27 vPY) (+3% vPY)
Back 51
Paraguay Retail Validation Study
100 20
80 2.7
65.8
60.7 58.1 0
60
46.2
41.9
40
-20
20
-26.1
-31.1 -29.9
0 -40 -35.9
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
• Overall precision index improved by 23.9 percentage points # Participating # Forms % Market
Outcomes
overestimation in 2021
• Fulfill sample design; Increase chain and independent 31 824 25%
pharmacy panels and/or incorporate more census data; (-22 vPY) (-195 vPY) (-7% vPY)
Increase participation
Back 52
Peru Retail Validation Study
100 91.8 91.1 90.6 89.3 20

85.1
80
0.1
0
60
-2.5
-6.2 -7.5
40 -9.6
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 31 1,421 52%
Back 53
Uruguay Retail+Mutuales Validation Study
100 89.4 20
86.7 84.2 85.3
76.8
80
1.5 1.3
0
60
-1.1 -0.8
-4.0
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
• No action required from the statistical point of view (no change vPY) (-2 vPY) (-2% vPY)
Back 54
Venezuela Retail Validation Study
100 89.6 91.3 20

88.0
80 74.3 6.8
0
60
-1.1 -0.7
-4.9
40
-20
20
0 -40
2017 2019 2020 2021 2017 2019 2020 2021
Participation

in 2021
in 2021 26 921 54%
Back 55
Europe
Countries
Austria Kazakhstan
Bosnia Latvia
Bulgaria Lithuania
Croatia Poland
Czech Republic Russia
Finland Serbia
France Slovakia
Greece Slovenia
Hungary Spain
Ireland Switzerland
Italy United Kingdom
Back 56
Austria Retail Validation Study

95.1 95.4 98.0 98.9
100 93.6 20
80
0
60
-0.6 -2.9
-4.2 -3.5
-6.9
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 17 486 15%
• Review projection levels (-1 vPY) (-51 vPY) (-1% vPY)
Back 57
Austria PharmaTrend Validation Study
100 94.0 95.9 92.6 93.6 94.6

20
80
2.2
0
60
-1.3 -2.2
-4.4 -4.4
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
Outcomes • Overall precision index improved by 1.0 percentage point # Participating # Forms % Market
• Overall bias turned from 2.2% underestimation in 2020 to
2.2% overestimation in 2021 17 472 15%
• Analyze root-cause for slight overestimation; Implement (-1 vPY) (-54 vPY) (-1% vPY)
enhanced universe update and adjust projection levels
Back 58
Austria OTC Validation Study
100 92.5 94.7 96.0

90.4 88.3 20
80
0
60
-2.8
-5.8
40 -8.8 -8.2 -8.2
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
Outcomes • Overall precision index declined by 2.1 percentage points # Participating # Forms % Market
in 2021 6 77 15%
• Improve quality of incoming data; Implement enhanced (-1 vPY) (-3 vPY) (-3% vPY)
universe update and adjust projection levels
Back 59
Austria Hospital Validation Study
100 93.2 20
89.3 89.3
84.2 82.7
80
2.4 2.4 0.1
0
60
-1.8 -1.9
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
• No action required from the statistical point of view (-2 vPY) (+1 vPY) (+1% vPY)
Back 60
Bosnia and Herzegovina Retail+Hospital Validation Study

100.0 99.4 99.7 96.5 99.3
100 20
80 4.6
0.1 1.0 1.9 0.1
0
60
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
• Overall overestimation improved by 1.8 percentage points
in 2021 14 402 34%
• No action required from the statistical point of view (-4 vPY) (-236 vPY) (-18% vPY)
Back 61
Bulgaria Retail Validation Study

95.0 95.3 97.3
100 89.5 92.0 20
80
0
60 -0.2 -0.1
-1.0 -0.5 -0.8
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 53 626 33%
Back 62
Bulgaria OTC Validation Study
100 93.2 93.5 20

87.8 88.9
80.5
80
2.0 0.4 0.4
0
60
-1.4 -0.4
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
• Overall bias turned from 0.4% underestimation in 2020 to
0.4% overestimation in 2021 27 108 24%
Back 63
Croatia Retail+Hospital Validation Study

99.8 99.2 99.9 99.5 98.7
100 20
80
1.2 0.7 0.9
0
60
-0.9 -0.6
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

2021
points in 2021 11 268 10%
• Increase the collaboration in the validation (+1 vPY) (+42 vPY) (-1% vPY)
Back 64
Croatia PharmaTrend Validation Study

99.2
100 93.4 92.3 95.0 93.9
20
80
0.6 0.2
0
60
-0.8 -1.0 -1.8
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

2021
in 2021 11 150 9%
• Increase collaboration in the validation (+1 vPY) (-4 vPY) (-2% vPY)
Back 65
Czech Republic Retail+Hospital Validation Study

98.8 99.3 98.6 98.0 98.5
100 20
80
0.0
0
60
-2.3 -2.3 -3.3 -2.9
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
• Overall bias turned from 2.9% underestimation to no bias in
2021 254 3,057 85%
*Government data used in validation since 2021
Back 66
Czech Republic PharmaTrend Validation Study

95.6 95.8 95.3 94.4 96.6
100 20
80
0
60
-1.7
-6.8 -5.8 -6.8 -6.2
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 149 1,615 55%
*Government e-prescription sales data used in validation since 2021
Back 67
Finland PharmaTrend Validation Study
100 95.3 96.3 94.8 93.7

91.7 20
80 5.3
1.5
0
60
-1.0 -1.3 -1.0
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
• Overall bias turned from 1.5% overestimation in 2020 to
1.0% underestimation in 2021 148 1,922 89%
• No action required from statistical point of view (+8 vPY) (+82 vPY) (-2% vPY)
Back 68
France Retail Validation Study

96.9 98.8 99.5 98.9 98.1
100 20
80
0.9 0.3 1.2 1.8 1.5
0
60
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

2021
in 2021 162 3,573 90%
Back 69
Greece Retail Validation Study
100 91.6 89.6 93.4 20

89.3 88.5
80
0.0
0
60
-1.5 -0.7 -1.1 -1.5
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

2021
2021 44 933 49%
• Explore channel distributions (-4 vPY) (+65 vPY) (+1% vPY)
Back 70
Greece OTC Validation Study
100 20
81.4 83.6 81.5 84.9
80 71.7
0
60
-3.8
40 -10.0
-20 -15.1 -14.1
20 -24.1
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

• Overall precision index declined by 13.2 percentage points Companies Validated Validated
in 2021
points in 2021 15 92 38%
• Explore channel distributions (-3 vPY) (+6 vPY) (+2% vPY)
Back 71
Hungary Retail+Hospital Validation Study
Precision 100% Bias 0.0%

99.5 98.9 99.5 99.9 100.0
100 20
80
0.1 0.3 0.2 0.0
0
60 -0.1
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

• Overall precision index improved slightly by 0.1 percentage Companies Validated Validated
points in 2021
2021 71 1,446 66%
Back 72
Hungary PharmaTrend Validation Study

96.8 96.6 97.4 97.2 98.2
100 20
80
0
60
-1.7 -0.7 -1.9 -1.1 -0.5
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

• Overall precision index improved by 1.0 percentage point in Companies Validated Validated
2021
in 2021 65 1,233 66%
Back 73
Hungary OTC Validation Study

96.8 98.0 99.4 97.9 99.4
100 20
80
0.8 0.2
0
60
-2.4 -0.6
-3.1
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
Back 74
Ireland PharmaTrend Validation Study
100 89.1 20
87.6
80
0
60
-1.0
-3.6
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
• Overall underestimation improved by 2.6 percentage Points
in 2021 113 1,532 89%
• No action required from statistical point of view (-4 vPY) (-11 vPY) (+3% vPY)
Back 75
Italy Retail Validation Study

97.8 96.2 97.1
100 91.7 93.4 20
80
0.6
0
60
-2.0 -0.8 -1.2
-3.4
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
underestimation in 2021 25 1,193 27%
Back 76
Italy PharmaTrend Validation Study
100 96.3 95.6 95.5

91.9 20
87.9
80
0
60
-1.7 -1.2 -1.3
-3.6 -4.4
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 24 1,141 27%
Back 77
Italy OTC Validation Study
100 91.2 94.2

89.6 20
82.9 82.4
80
0
60
-2.4
40 -9.3 -8.8 -8.5
-20 -13.2
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

2021
in 2021 14 86 12%
Back 78
Italy Hospital Validation Study
100 90.8 20
85.2 88.1
82.2
78.3
80
0
60
-6.7 -8.8 -8.4 -7.1 -7.3
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
Outcomes • Overall precision index declined by 3.9 percentage points in 2021

# Participating # Forms % Market
• Overall underestimation increased slightly by 0.2 percentage Companies Validated Validated
points in 2021
• Non-Retail distribution is undergoing several changes and this 12 272 28%
might explain increased variability. Continue implementation of
quality-improving actions (incl. improvements of panel coverage)
(-4 vPY) (-34 vPY) (-1% vPY)
Back 79
Kazakhstan Retail+Hospital Validation Study
100 91.9 90.9 91.5 94.3 16.0

20
80 2.9 4.3 4.6 5.1

62.3
0
60
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
• Overall precision index improved by 2.8 percentage points # Participating # Forms % Market
Outcomes
• Overall overestimation increased by 0.5 percentage points
in 2021
• Increase participants of study; Work with participants more 42 399 9%
closely and focus their attention on more accurately filling in (-27 vPY) (-257 vPY) (-5% vPY)
survey; Add two additional wholesalers to panel
Back 80
Latvia Retail Validation Study
100 94.7
89.5 87.8 90.1 20 14.3
83.6
80 4.7 4.2 2.9
1.2
0
60
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 14 253 10%
Back 81
Lithuania Retail Validation Study

95.8 98.8 97.4 97.3
100 94.7
20
80
0.3 0.1
0
60
-0.9 -1.1
-5.4
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 19 428 22%
• Review projection levels (-6 vPY) (-278 vPY) (-14% vPY)
Back 82
Poland Retail+Hospital Validation Study

95.3 94.6 97.7 97.1 98.1
100 20
80 2.6 3.1 1.4 0.4

0
60
-0.6
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

point in 2021
• Increase the collaboration in the validation (-15 vPY) (-450 vPY) (-14% vPY)
Back 83
Poland PharmaTrend Validation Study
100 92.6 92.9 94.2

86.9 89.6 20
80
0
60
-1.9 -3.2 -2.1
-4.6 -5.1
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
in 2021 34 693 16%
• Annual revision of projection factors; Increase the (-19 vPY) (-410 vPY) (-14% vPY)
collaboration in the validation
Back 84
Poland OTC Validation Study
100 20
88.3 87.5 88.2
82.7
80 75.4
0
60
-1.7 -2.6
-6.0 -5.7 -5.4
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
in 2021 21 224 15%
• Annual revision of projection factors; Increase the (-16 vPY) (-127 vPY) (-16% vPY)
collaboration in the validation
Back 85
Russia Retail+Hospital Validation Study
100 88.8 89.0 20

88.0 86.4
83.2
80
0
60
40 -11.7 -9.8 -11.4 -10.1

-20 -15.3
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
in 2021 142 2,283 45%
• Improved the quality by adding new important chains in the (+17 vPY) (+183 vPY) (+8% vPY)
panel
Back 86
Serbia Retail+Hospital Validation Study

96.1 97.8 98.2 98.5
100 94.4
20
80 3.4 1.1 0.0

0
60 -0.2
-2.4
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

points in 2021
• Overall bias turned from no bias to 0.2% underestimation in
2021 22 441 39%
Back 87
Serbia PharmaTrend Validation Study
100 93.3 20
80
0
60
-5.4
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

• Overall precision index at 93.3% in 2021 Companies Validated Validated
• Overall underestimation at 5.4% in 2021
• Improve the panel coverage; Fine tune the outlier detection 21 287 35%
process (vPY) (vPY) (vPY)
Back 88
Slovakia Retail+Hospital Validation Study

99.4 99.6 98.3 99.7 99.7
100 20
80
0.2
0
60 -0.1 -0.2 -0.4 -0.6
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

• Overall precision index remained unchanged in 2021 Companies Validated Validated
in 2021 12 508 18%
Back 89
Slovakia PharmaTrend Validation Study
100 93.1 95.4 93.6 93.5 96.4

20
80
0
60
-0.7 -2.3 -0.4
-3.5 -3.5
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 12 435 18%
Back 90
Slovakia OTC Validation Study

98.2 95.7 95.7
100 90.2 94.0
20
80
0.0
0
60
-2.8 -2.9 -0.9
-3.7
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 9 75 13%
Back 91
Slovenia Retail+Hospital Validation Study

98.1 99.7 99.3 98.7
100 95.3
20
80
0.4 1.1
0
60 -0.1
-2.5 -1.0
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

points in 2021
points in 2021 13 268 11%
• No action required from the statistical point of view (no change vPY) (-24 vPY) (-1% vPY)
Back 92
Spain Retail Validation Study
100 95.8 95.2 93.6 94.8

20
80
0.1 1.5 1.1
0
60
-0.5
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
• Overall overestimation improved slightly by 0.4 percentage
points in 2021 26 997 20%
Back 93
Spain PharmaTrend Validation Study
100 95.9 95.0 92.3 94.3

20
80
0
60
-3.9 -3.2 -2.7
-5.2
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
in 2021 26 964 16%
• Increase manufacturer participation in the validation; (+5 vPY) (+220 vPY) (+4% vPY)
Review projection levels
Back 94
Spain OTC Validation Study
100 92.9 89.5 92.9 90.7 20
80
0.7 0.8
0
60
-3.0 -2.8
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
• Increase Manufacturer participation in the validation; (+1 vPY) (+12 vPY) (+4% vPY)
Review projection levels
Back 95
Switzerland Retail+Hospital Validation Study

98.8 99.8 99.7 100.0 99.6
100 20
80
0
60
-1.0 -0.8 -0.6 -0.5 -1.2
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
• Overall underestimation increased by 0.7 percentage
points in 2021 50 1,861 41%
Back 96
Switzerland PharmaTrend Validation Study
100 95.8 95.8 95.5 96.4 94.6

20
80 3.3 2.8
1.0 2.3
0
60
-2.6
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 179 3,707 91%
• Enhance quality control metrics; Review projection levels (+5 vPY) (-5 vPY) (-1% vPY)
Back 97
Switzerland OTC Validation Study
100 93.7 94.0 94.5 95.4 93.5 20
80 6.2
2.3 3.2 3.8
0
60
-3.7
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

2021
in 2021 103 1,087 93%
• Enhance quality control metrics; Review projection levels (-3 vPY) (-41 vPY) (-3% vPY)
Back 98
United Kingdom Retail Validation Study
100 93.6 93.2 20
80
0
60 -0.3
-7.4
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2020
Participation
• Result are based on Rx count at Molecule/Form/ # Participating # Molecule/Form/ % Market
Outcomes
Strength level Molecules Strength Validated Validated
• Overall precision index declined by 0.4 percentage points in
2021
• Overall underestimation improved by 7.1 percentage points 617 2,144 94%
in 2021 (-16 vPY) (No change vPY) (+2% vPY)
• No action required from the statistical point of view
*2020 validation has been refreshed to be comparable with 2021 validation
Back 99
United Kingdom Hospital Validation Study

100.0 100.0
100 20
7.9
80
0
60
-0.7
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2020
Participation
Outcomes # Participating # Molecule/Form/ % Market

• Result are based on Molecule/Form/Strength level Molecules Strength Validated Validated
• Overall precision index remained unchanged in 2021
• Review product bridging (+197 vPY) (+296 vPY) (+38% vPY)
Back 100
Africa, Middle East, South Asia
Countries
Africa Middle East
• Algeria • Egypt
• Morocco • Jordan
• Tunisia • Kuwait
• Lebanon
South Asia • Saudi Arabia
• Bangladesh • Turkey
• United Arab Emirates
Back 101
Algeria Retail Validation Study
100 20
74.0 77.2
80 69.4 3.5
68.0 68.6 0.2
0
60
-0.7
-4.8
40 -9.8
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
Back 102
Morocco Retail Validation Study

96.1 97.9 97.1
100 93.5 20
88.8
80
0
60
-2.1
-5.3 -7.0
40 -10.1 -11.5
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 73 549 30%
• Continue implementation of quality-improving actions (-5 vPY) (-30 vPY) (+7% vPY)
Back 103
Tunisia Retail Validation Study

98.4 97.1 98.8 99.7
100 20
80
0.6 0.9
0
60
-2.5
-7.2
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 27 732 44%
Back 104
Egypt Retail Validation Study

99.6 99.7
100 95.3 92.6
88.5 20
80 4.0 4.3 3.1

1.1 1.2
0
60
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 50 520 24%
Back 105
Jordan Retail Validation Study
100 91.9 89.9 93.4 20

85.9
80
0
60
-1.1
-8.5 -6.4
40 -11.7
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
points in 2021 27 758 47%
Back 106
Kuwait Retail Validation Study

100.0 100.0 98.7 100.0 98.6
100 20
80
0.2 0.2
0
60 -0.1
-1.1 -1.0
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
• Overall bias turned from 0.2% overestimation to 1%
Back 107
Lebanon Retail Validation Study

96.7
100 91.8 90.3 90.6 20
86.9
8.4
80 6.0
1.3 1.9
0
60
-4.9
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
Back 108
Saudi Arabia Retail Validation Study

100.0 100.0 100.0 100.0 99.4
100 20
80 2.7 1.9 1.2 0.9

0
60 -0.1
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
Back 109
Turkey Retail Validation Study

99.9 100.0 99.9 99.9 99.9
100 20
80
0.0
0
60
-2.5 -1.6 -1.8 -1.8
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

2021 75 1,250 52%
Back 110
United Arab Emirates Retail Validation Study

99.8 100.0 99.8 100.0 98.7
100 20
80 2.6
1.2 0.9 2.3
0
60
-0.4
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 30 830 47%
Back 111
Bangladesh Retail Validation Study
100 20
84.0 82.6
77.6
80 72.4 72.6
0
60
40
-20 -15.1 -14.3
-17.1
-19.9 -20.1
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
in 2021 23 2,127 46%
• Conduct census activity and implement its results for (+6 vPY) (+2 vPY) (-8% vPY)
adjustment of projection factors
Back 112
Asia Pacific
Regions/Countries
Greater China Southeast Asia
• China • Indonesia
• Hong Kong • Malaysia
• Pakistan
• Singapore
Pacific Asia • Thailand
• South Korea • Vietnam
• Japan
Back 113
China Hospital Validation Study

96.5 97.5 97.8
100 20
88.5
80
0
60
-6.1 -7.0 -6.2
40
-20 -14.1
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
in 2021 24 158 2%
• Continue to strengthen panel and evaluate alternative data (+2 vPY) (+14 vPY) (-2% vPY)
sources in long-term
Back 114
Hong Kong Retail Validation Study
100 20
80.0 81.5 82.7 83.0
80 75.4
0
60
-9.0 -9.2 -9.0 -7.3 -7.6

40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 47 803 26%
Back 115
South Korea Retail Validation Study
100 90.1 20
86.9 87.6 86.3 82.5
80
0
60
-7.4
40 -10.1
-20 -13.5
-17.5 -17.6
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
• Overall underestimation increased slightly by 0.1
percentage points in 2021 11 473 7%
• Review projection level and panel composition. Check (-3 vPY) (-226 vPY) (-1% vPY)
completeness and replace inadequate panel
Back 116
South Korea OTC Validation Study
100 20
83.3 83.1 80.6
80 73.3
64.2
0
60
-3.6
40
-20 -14.3 -13.8
-16.6
-19.9
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
in 2021 6 99 5%
• Review projection level and panel composition. Check (-1 vPY) (-27 vPY) (-1% vPY)
completeness and replace inadequate panel
Back 117
South Korea Hospital Validation Study
100 20
80
60.7 62.8
57.0 0
60 50.4 46.9 -2.3
40 -9.4 -9.1
-20 -15.8
-19.1
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
in 2021 11 128 4%
• Review projection level panel composition. Improve QC (-2 vPY) (-42 vPY) (-1% vPY)
process
Back 118
Japan Retail+Hospital Validation Study

99.8 99.6 99.3 99.3
100 20
80
0.3 0.0 1.1
0
60 -0.1
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

overestimation in 2021 30 1,728 27%
Back 119
Indonesia Total Market Validation Study
100 20
80
64.7 61.4 0
60 50.9 -0.4
44.1 -3.2
39.0 -8.7 -7.7 -6.6
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Validation Participation
Outcomes • Overall precision index declined by 5.1 percentage points in 2021 # Participating # Forms % Market
• Overall underestimation improved by 6.2 percentage points Companies Validated Validated*
in 2021
• New data sources from chain pharmacies and Nielsen general
&modern trade are integrated, meanwhile, IQVIA continues to 46 1,322 15%
expand the number of contributors and improve data coverage (-4 vPY) (-101 vPY) (-4% vPY)
with more partners
*% Market Validated is calculated based on units, in terms of values, % Market can be validated has reached at 50%
Back 120
Malaysia Combined Validation Study
100 20
85.4 83.2 84.5
80
0
60
-2.3
-7.7 -6.7
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
Outcomes • Overall precision index increased by 1.3 percentage points # Participating # Forms % Market
• Overall underestimation declined by 1.0 percentage points
in 2021 104 1,510 50%
• Continue to secure additional direct data and panels; (+29 vPY) (+98 vPY) (+6% vPY)
Leverage AIML powered methodology to improve further
Back 121
Pakistan Retail Validation Study

95.9 97.4 95.6 98.4
100 94.4 20
80
0
60 -0.7 -0.7 -0.7
-2.7 -1.3
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
• Overall underestimation remained unchanged at 0.7% in
2021 50 1,834 52%
• Maintain the participation level of the validation study (-7 vPY) (-202 vPY) (-12% vPY)
Back 122
Singapore Combined Market Validation Study
100 20
80 69.1 70.5 71.9 70.3 70.4

0
60
-4.1 -5.7 -5.1 -4.5
-6.7
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
• Overall underestimation improved slightly by 0.6 percentage
points in 2021 83 1,198 39%
• Continue to secure additional direct data and panels; (+10 vPY) (+140 vPY) (+4% vPY)
Leverage AIML powered methodology to improve further
Back 123
Thailand Retail Validation Study
100 20
83.9 84.5 83.9
79.4
80
0
60 -0.9 -1.3 -1.7 -2.4
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation

in 2021
in 2021 81 913 18%
• Continue to maintain data consistency in long term (-5 vPY) (-238 vPY) (-1% vPY)
Back 124
Vietnam Total Market Validation Study
100 20
79.7 81.5 81.5 79.5 80.1
80
0
60
-3.7 -1.7 -1.5 -2.9 -3.3
40
-20
20
0 -40
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Participation
• Overall underestimation increased slightly by 0.4
percentage points in 2021 98 1,499 23%
• Continue to secure additional benchmark data and panels (+7 vPY) (+49 vPY) (no change vPY)
to improve further
Back 125
Methodology
Back
126
• Distribution Channels validated

Validation Studies
1 • Decile Inclusion/Exclusion Schema
• How IQVIA measures Accuracy
• Bias (interpretation – calculus – limitations)

•
Accuracy
2 •
•
Overestimation (illustration)
Underestimation (illustration)
Precision (interpretation – calculus – illustration)
• Elapsed days after reporting period (definition)

Timeliness
3 • On-target % (definition)
• On-target % vs. On-time % (how both compare)
127
Distribution Channels validated
ACTS compares the Manufacturer’s ex-factory sales with IQVIA’s audited channels
Manufacturer IQVIA IQVIA

Ex-Factory Sell-In Sell-Out
Retail
Retail Sell-in Pharmacy Sell-Out
Wholesaler Patient
Hospital Sell-in Consumption
Hospital
Pharmacy
128
ACTS surveys 95% of the units market in the audited channel
Small 5% of product forms get excluded
Decile Inclusion/Exclusion Schema
Total Market Decile 1 breakdown ACTS breakdown

Upper Limit Total Upper Limit Total Upper Limit Total
Decile #Forms Segment Decile #Forms Segment Decile #Forms Segment
(FY Units) (FY Units) (FY Units) (FY Units) (FY Units) (FY Units)
1.01- Small 5%
1 16,746 288,316 421,249,733 Small 10% 1.01 12,546 20,349 42,128,674 15,623 210,803,990 210,803,990
1.05 excluded
Next 10% Small 15%
2 874 795,338 421,315,079 1.02 1,386 44,263 42,143,302 1.06-2 1,997 631,760,822 631,760,822
included included
Low 5% Medium
3 385 1,541,503 421,089,812 1.03 771 67,192 42,167,630 excluded 3-5 709 1,263,890,256 1,263,890,256 30%
Medium included
30%
Large 50%
4 206 2,782,743 421,471,438 Included 1.04 530 93,364 42,200,606 6-10 132 2,103,828,718 2,103,828,718
included
5 118 4,572,060 421,329,006 1.05 390 122,163 42,163,778
6 66 9,143,464 427,161,847 1.06 313 148,246 42,209,105
7 36 15,617,602 424,827,107 1.07 258 181,048 42,244,392

Large 50% Next 5%
8 20 34,458,310 444,648,076 1.08 215 214,823 42,284,130
included included
9 8 89,798,547 507,434,006 1.09 183 248,645 42,301,336
10 2 206,855,970 299,757,682 1.10 154 288,316 41,406,780
Total 18,461 4,210,283,786 16,746 421,249,733 18,461 4,210,283,786 4,210,283,786
ACTS 1,715 3,789,034,053 1,123 210,445,743 2,838 3,999,479,796 3,999,479,796
FY = Full Year; This page only serves as a simplified illustration!
129
Validation Studies
How IQVIA measures Accuracy
Once a year, IQVIA supplies clients with a software that includes estimated yearly
1 sales volumes for each product pack
Clients enter their actual ex-factory sales volume based on what they supplied to
2 the validated market channel, e.g., retail pharmacies
Validation Studies then produce two key quality statements:

• BIAS: Average over/underestimation of the market or a single product
3
• PRECISION: Percentage of product forms weighted by its IQVIA units within a
predefined deviation range
130
Validation Metrics
Bias: % of Over- or Underestimation
Interpretation Calculus Limitations

• The objective of Bias is to provide a • Inclusion of unaudited market
robust estimation of average deviation Pack Audit Units Real Units R-Values channels (e.g., private clinics/
between IQVIA data and Real data. A 1,000 900 1.111 dispensing doctors or tender) into
• Bias measures the level of deviation B 1,200 1,500 0.800
real sales data affects bias
caused by systematic errors, e.g. measurement. Participants are not
- Projecting to a too small universe C 4,000 3,800 1.053 always able to segregate their sales
may result in a negative bias D 6,500 7,000 0.929 to the validated segment.
(=underestimation) or • Low validation coverage may lead
E 7,200 7,400 0.973 to an inaccurate bias measure.
- Systematically collecting incomplete
data from panels may lead to Sum 19,900 20,600 0.966 The higher the number of participants
underestimated projected results or the better.
- Not capturing 100% of the market, • Purposive selection of therapeutic
say because of unaudited channels Bias = -3.4% classes or products into the validation
(like private clinics) is another reason data set provides an unrepresentative
for Bias (here underestimation). Average over/underestimation (Bias) in % bias measure.
• Extreme R-Values distort robustness.
Therefore, R-Values outside ±52.5% 𝑻𝒐𝒕𝒂𝒍 𝑨𝒖𝒅𝒊𝒕 𝒖𝒏𝒊𝒕𝒔 𝑜𝑓 𝑎𝑙𝑙 𝑣𝑎𝑙𝑖𝑑𝑎𝑡𝑒𝑑 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑓𝑜𝑟𝑚𝑠
= ( 𝑻𝒐𝒕𝒂𝒍 𝑹𝑬𝑨𝑳 𝒖𝒏𝒊𝒕𝒔 𝑜𝑓 𝑎𝑙𝑙 𝑣𝑎𝑙𝑖𝑑𝑎𝑡𝑒𝑑 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑓𝑜𝑟𝑚𝑠 -1) * 100
interval are excluded.
131
Clients Ex-Factory data vs. IQVIA’s audited channel data
Example 1: Overestimation
Overestimation 10 units overestimated
Units projected
35 units added through projection
110 units reported
100 units sold
Units sold
Bias: 75 actual units collected
110/100 = 1.100 (R-Value) Units collected
110/100 = +10% overestimated
Client IQVIA
132
Clients Ex-Factory data vs. IQVIA’s audited channel data
Example 2: Underestimation
Underestimation 10 units underestimated
Units projected 15 units added through projection

100 units sold
90 units reported
Units sold
Bias: 75 actual units collected
90/100 = 0.900 (R-Value) Units collected
90/100 = -10% underestimated
Client IQVIA
133
Validation Metrics
Precision: % of products in a fixed range of deviation
Interpretation Calculus
• Precision index measures the R-Value R-Value Distribution R-Value Distribution
dispersion, i.e., it measures how many
From To # Forms 1000
R-Values (weighted by its IQVIA units)
lay inside a ±22.5% interval around the 0.475 0.575 15
770
overall Bias. 0.575 0.675 35 800
# of products
0.675 0.775 55 590
• Different to Bias which measures systematic 600
effects, the Precision Index measures the 0.775 0.875 230 410
random effect of a sample. 0.875 0.975 590 ∑= 2,100 R-Values
400
230
0.975 1.075 770 inside the ±22.5%
• A low precision index usually indicates that 200 100
1.075 1.175 410 interval 55 45 25
the underlying sample size is too small/not 15 35 5
representative and also causes wrong 1.175 1.275 100 0
0.475-0.575
0.575-0.675
0.675-0.775
0.775-0.875
0.875-0.975
0.975-1.075
1.075-1.175
1.175-1.275
1.275-1.375
1.375-1.475
1.475-1.575
market shares and rankings.
1.275 1.375 45
• A high precision index indicates a 1.375 1.475 25
representative sample size and is a result of 1.475 1.575 5
consistent projected numbers. This is being
measured around the average Bias which Total 2,280 R-Value
either can be negative or positives. 𝟐, 𝟏𝟎𝟎
𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 = 𝐱 𝟏𝟎𝟎 = 𝟗𝟐. 𝟏%
𝟐, 𝟐𝟖𝟎
134
Timeliness
Speed of Delivery
Definition On-Target % vs. On-Time %

• “Elapsed days after reporting period”
On-Target % On-Time %
measures the number of days, after
the end of the reporting period until Country/Region*Audit*Period Country*Audit*Period*Client
Transaction
time of delivery on MIDAS. (period = data month!) (period = calendar month!)
• “On-Target %” measures how Measure Days after Period (DAP) Actual vs. Schedule
many data deliverables were
shipped on MIDAS within a Monthly: Actual < 30 days
Threshold Actual < Schedule (agreed)
Quarterly: Actual < 45 days
certain number of days.
• Thresholds: Threshold is individual by country
Threshold is applied consistently to
Handling and considers local agreements
- Monthly: Actual ≤ 30 days any country and audit.
with clients.
- Quarterly: Actual ≤ 45 days
Metric measures if deliverable is within Metric measures if deliverable is
• Databases in scope: Interpretation threshold (DAP), hence the time it took as per the plan. It considers
- Monthly MIDAS after period to build databases. agreed delivery dates with clients.
- Quarterly MIDAS Real world “I received August data with delay” “I got a late delivery in August”
Publication ACTS Annual Report n/a
DAP data being used is also published on MIDAS Delivery Performance: https://customerportal.imshealth.com/sites/imsportal/product-support/midas-products-psa/iqvia-midas/psa/database-update-schedules
135
ACTS content now available on IQVIA Customer Portal
How to access?
Access Countries/Regions available Alerts Subscriptions

If you are new to the customer portal, Algeria Estonia Mexico Switzerland If you would like to get notified about
please self-register here. Once you got new ACTS content added to the portal,
Argentina Finland Morocco Thailand
your account set up, please access please enable alert notifications under
Austria France Pakistan Tunisia
ACTS country results here: ACTS My Settings > Manage IQVIA Alerts
Country Reports. Bangladesh Germany Peru Turkey Subscriptions. Please select following
Bosnia Greece Philippines UAE subscription name:
Brazil Hong Kong Poland UK
• “IQVIA MIDAS”
Bulgaria Hungary Portugal Uruguay
Canada Indonesia Russia USA and your individual frequency and
Cen. America Italy Saudi Arabia Venezuela notification type:
Chile Japan Serbia Vietnam
Colombia Jordan Singapore
Croatia Kazakhstan Slovakia
Czech R. Kuwait Slovenia
Dominican R. Latvia South Africa
Ecuador Lebanon South Korea
Egypt Lithuania Spain
136
2022 ACTS Annual Report
Presented to you by IQVIA’s Global
Data Science and Advanced Analytics
Team with offices in Plymouth Meeting
(United States), Frankfurt (Germany)
and Beijing (China)
Thank You

2022-Global Acts-Annual-Report

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

2022-Global Acts-Annual-Report

Uploaded by

Copyright:

Available Formats

2022 ACTS Annual Report

Statistical Quality Assurance applied to

Global Data Science and Advanced Analytics

+ About this report

+ IQVIA Market Prognosis

*number of distinct countries

90+ 150+ 10K 1.6M 4M+

40+ years of local and

Ongoing updates as new/changed

Data Type Results by data type (Retail, Hospital, PharmaTrend/Sell-out, OTC)

Countries Impacted List of countries with improved or deteriorated results

Coverage Results Summary

Global Retail Precision Index (%) Improvement Deterioration

Bolivia 73.2 +13.0 Greece 88.5 -4.9

Uruguay 89.4 +12.6 South Korea 82.5 -3.8

Algeria 77.2 +7.8

Global Hospital Precision Index (%) Improvement Deterioration

Russia 86.4 +3.2 Croatia 98.7 -0.8

Bosnia 99.3 +2.8

Global PTR Precision Index (%) Improvement Deterioration

Slovakia 96.4 +2.9 Switzerland 94.6 -1.8

Czech Republic 96.6 +2.2

Global Retail OTC Precision Index (%) Improvement Deterioration

Argentina 89.8 +8.0 Mexico 76.8 -8.7

Bulgaria 93.5 +4.6 Austria 88.3 -2.1

Statistics featured in this section pertain to number of days, after the

“Elapsed days after period” and “Percent On-Target” are the

Number of deliverables used for measuring Timeliness: Also reported

• MIDAS Specialty Definition

• Bias and Precision by Specialty markets (Anti-TNF, Hep-B & HIV,

Anti-TNF Hepatitis B Crohn’s

J05C5 L01C3 L01G5 L01J0 L02A2 V03C0 B02C9 H02A1 L03B3

J05C9 L01C4 L01G9 L01L1 L02A3 V03D0 B02D1 H04C0 L03B9

J05D1 L01C9 L01H0 L01X1 L02A9 B02D2 H04E0 M05B3

J05D2 L01D0 L01H1 L01X2 L02B1 B02D3 J06C0 M05B9

J05D3 L01F0 L01H2 L01X3 L02B2 B03C0 J06E0

J05D9 L01G0 L01H3 L01X4 L02B3 G02X9 J06H4

2012 2017 2022 2027

10 developed Other developed Pharmerging Global

Accuracy Results Survey Basis

-2.6 surveyed Canada Switzerland Canada France Austria Mexico

Validity of Results by IQVIA’s regional BU and leading 10 pharmaceutical

Commentary Commentary on selected markets

Average 5-year error across 45 Market Prognosis countries was

Three of the five Market Prognosis regions showed deteriorated

For the leading 10 countries, four of them showed 5-year average

France +0.3 FR -3.7

North America 4.6 -2.4 Brazil -5.4 BR -5.7

United States China Japan

• The underestimation of the 1-year forecast for 2021 was

Germany France Italy

• Furthermore, the COVID-19 pandemic related

United Kingdom Spain Canada

• The resilient Brazilian pharmaceutical market

Precision 95.0% Bias -7.3%

100 95.6 96.5 95.6 96.0 95.0

-6.4 -7.6 -7.5 -7.3

Precision 99.9% Bias -2.1%

Outcomes # Participating # Forms % Market

Precision 99.7% Bias -0.2%

Outcomes # Participating # Forms % Market

Precision 100% Bias 0%

Outcomes # Participating # Forms % Market